Why Indian Hospitals Need AI-Powered Evidence at the Oncology Bedside
India’s Oncology Expansion Is Outpacing Its Evidence Infrastructure
India’s cancer burden is growing at an alarming rate. An estimated 1.57 million new cancer cases are diagnosed annually, and that number is climbing at roughly 6.8% per year. Hospital chains have responded by building capacity: Apollo Hospitals operates 13 cancer centres across 12 cities with 23–25 linear accelerators. Max Healthcare derives nearly 25% of its inpatient revenue from oncology. HCG reported a 17% year-on-year oncology revenue increase. Fortis sees oncology contributing 16.4% of hospital income, potentially outpacing cardiology.
But capacity is not the same as capability. Adding beds, hiring oncologists, and purchasing equipment solves the access problem. It does not solve the evidence problem. And the evidence problem in oncology is enormous.
What the Evidence Gap Actually Looks Like
Here is a scenario that plays out in Indian hospitals every day. An oncologist in the department is managing a patient with stage IIIA non-small cell lung cancer. The patient is 62 years old, diabetic, has a specific molecular profile with an ALK rearrangement, and is on medications for hypertension and Type 2 diabetes. The oncologist needs to make a treatment decision that accounts for current NCCN guidelines for ALK+ NSCLC, drug interactions between the targeted therapy and the patient’s diabetes and hypertension medications, the latest published evidence on outcomes for ALK+ patients with comorbidities, and whether the patient might be eligible for any relevant clinical trials.
In theory, all of this information exists. In practice, finding it, synthesizing it, and applying it to this specific patient takes significant time—time that the oncologist does not have when they are seeing 25–30 patients a day. The result is that treatment decisions rely heavily on experience and memory rather than real-time evidence. This is not a criticism of Indian oncologists. It is a structural limitation of how evidence reaches the point of care.
Why Your Current Systems Are Not Enough
Most Indian hospitals that have invested in digital infrastructure have focused on Hospital Information Systems and EMRs—and rightly so. ABDM (Ayushman Bharat Digital Mission) compliance, NABH accreditation, ABHA ID integration, and billing automation are essential operational priorities. Apollo, Max Healthcare, and Sankara Nethralaya have achieved HIMSS Stage 6 EMR adoption.
But these systems were built for data capture and workflow management, not clinical intelligence. Your HIS stores the patient’s diagnosis. It does not tell the oncologist what the latest guidelines recommend for that diagnosis with that specific molecular profile. Your EMR records the medication list. It does not flag that the combination of the proposed targeted therapy with the patient’s existing medications creates a clinically significant interaction.
The standard drug interaction alerts built into most Indian HIS systems generate so many false positives in oncology that clinicians override 70–90% of them. This is alert fatigue, and it is worse in oncology than in any other specialty because cancer treatment inherently involves medications with narrow therapeutic windows and expected interactions.
What AI-Powered Clinical Decision Support Changes
A clinical decision support system built for oncology works differently. Instead of firing generic alerts, it synthesizes the patient’s complete clinical picture—staging, molecular profile, treatment history, comorbidities, current medications—against current evidence and guidelines. The output is not an alert. It is a synthesized clinical picture that helps the oncologist make a more informed decision.
OneRx is an example of a platform designed for exactly this context. Its Treatment Planning module presents evidence-based pathways adjusted for the patient’s specific staging and molecular characteristics. Its Cancer Staging feature helps ensure TNM classification is complete and consistent with current AJCC criteria. Its Drug Interactions module checks across the full medication list with oncology-specific knowledge. Its Biomarker Interpretation feature maps molecular findings against current targeted therapy and immunotherapy options. And its Clinical Guidelines module is continuously updated with the latest NCCN, ESMO, and Indian guideline recommendations.
For a hospital oncology department, this means a physician can access all of these evidence streams within a single platform, without leaving their workflow, in the time it takes to review a patient chart.
The Business Case for Hospital Leaders
Hospital administrators think in terms of outcomes, efficiency, and economics. The case for AI-powered oncology decision support maps to all three.
Outcomes: Guideline-concordant care is measurable. Hospitals that can demonstrate higher rates of evidence-based treatment decisions attract better oncologists, secure more clinical trial partnerships, and improve NABH quality scores. Insurance companies and government schemes increasingly require evidence of protocol adherence for reimbursement.
Efficiency: Tumor board preparation is faster when oncologists arrive with AI-synthesized patient summaries. Medical information queries decrease when a clinical intelligence platform answers common questions proactively. Treatment planning time per patient can be reduced meaningfully.
Economics: Suboptimal first-line treatment decisions lead to costly regimen changes, extended hospital stays, and adverse events. India’s average medical expense per hospitalised cancer case in metropolitan areas was over INR 68,000 per case. Reducing regimen changes and adverse events has a direct bottom-line impact.
Starting Small, Scaling Intelligently
The most successful implementations start with a single department or a pilot program. Begin with your oncology department—it has the highest clinical complexity and the clearest evidence gap. Introduce a clinical intelligence platform alongside existing HIS systems as a complementary layer, not a replacement. Measure specific metrics: time spent searching for clinical information, protocol deviation rates, tumor board preparation time, clinician satisfaction.
India’s EHR market reached USD 671 million in 2024 and is growing at 8.18% CAGR. Digital health investment is accelerating. The hospitals that integrate clinical AI into their oncology workflows now will be the ones that set the standard for what evidence-based cancer care looks like in India.